---
title: Assessing the Applicability of Cardiac Myosin Inhibitors for Hypertrophic Cardiomyopathy
  Management in a Large Single Center Cohort
date: '2024-07-30'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39076310/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240730181641&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: This study highlights a significant discrepancy between
  patient demographics in clinical trials and those encountered in routine HCM clinical
  practice. Despite promising results from the initial randomized clinical trials
  that led to the approval of Mavacamten, the selected patient population only represents
  a small part of the HCM patient cohort seen in routine clinics. This study advocates
  for further expanded randomized clinical trials with broader inclusion criteria
  to ...'
disable_comments: true
---
CONCLUSIONS: This study highlights a significant discrepancy between patient demographics in clinical trials and those encountered in routine HCM clinical practice. Despite promising results from the initial randomized clinical trials that led to the approval of Mavacamten, the selected patient population only represents a small part of the HCM patient cohort seen in routine clinics. This study advocates for further expanded randomized clinical trials with broader inclusion criteria to ...